Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma.
Bollu LR, Bommi PV, Monsen PJ, Zhai L, Lauing KL, Bell A, Kim M, Ladomersky E, Yang X, Platanias LC, Matei DE, Bonini MG, Munshi HG, Hashizume R, Wu JD, Zhang B, James CD, Chen P, Kocherginsky M, Horbinski C, Cameron MD, Grigorescu AA, Yamini B, Lukas RV, Schiltz GE, Wainwright DA. Bollu LR, et al. Among authors: matei de. J Med Chem. 2022 Dec 8;65(23):15642-15662. doi: 10.1021/acs.jmedchem.2c00771. Epub 2022 Nov 21. J Med Chem. 2022. PMID: 36410047 Free PMC article.
Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium.
Barber EL, Chen S, Pineda MJ, Robertson SE, Hill EK, Teoh D, Schilder J, O'Shea KL, Kocherginsky M, Zhang B, Matei D. Barber EL, et al. Cancer Res Commun. 2022 Oct;2(10):1293-1303. doi: 10.1158/2767-9764.crc-22-0147. Epub 2022 Oct 28. Cancer Res Commun. 2022. PMID: 36388466 Free PMC article. Clinical Trial.
Metabolic dependencies and targets in ovarian cancer.
Zhang Y, Wang Y, Zhao G, Orsulic S, Matei D. Zhang Y, et al. Pharmacol Ther. 2023 May;245:108413. doi: 10.1016/j.pharmthera.2023.108413. Epub 2023 Apr 13. Pharmacol Ther. 2023. PMID: 37059310 Review.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer.
Lheureux S, Matei DE, Konstantinopoulos PA, Wang BX, Gadalla R, Block MS, Jewell A, Gaillard SL, McHale M, McCourt C, Temkin S, Girda E, Backes FJ, Werner TL, Duska L, Kehoe S, Colombo I, Wang L, Li X, Wildman R, Soleimani S, Lien S, Wright J, Pugh T, Ohashi PS, Brooks DG, Fleming GF. Lheureux S, et al. Among authors: matei de. J Immunother Cancer. 2022 Mar;10(3):e004233. doi: 10.1136/jitc-2021-004233. J Immunother Cancer. 2022. PMID: 35288469 Free PMC article. Clinical Trial.
28 results